Establishment Labs Holdings Inc
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgeries. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force… Read more
Establishment Labs Holdings Inc (ESTA) - Net Assets
Latest net assets as of September 2025: $16.36 Million USD
Based on the latest financial reports, Establishment Labs Holdings Inc (ESTA) has net assets worth $16.36 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($338.89 Million) and total liabilities ($322.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.36 Million |
| % of Total Assets | 4.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -29.17% |
| 10-Year Change | N/A |
| Growth Volatility | 108.1 |
Establishment Labs Holdings Inc - Net Assets Trend (2016–2024)
This chart illustrates how Establishment Labs Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Establishment Labs Holdings Inc (2016–2024)
The table below shows the annual net assets of Establishment Labs Holdings Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $53.09 Million | +188.64% |
| 2023-12-31 | $18.39 Million | +324.74% |
| 2022-12-31 | $-8.19 Million | -116.13% |
| 2021-12-31 | $50.74 Million | -32.31% |
| 2020-12-31 | $74.96 Million | +89.23% |
| 2019-12-31 | $39.61 Million | -42.99% |
| 2018-12-31 | $69.48 Million | +1486.10% |
| 2017-12-31 | $-5.01 Million | +81.04% |
| 2016-12-31 | $-26.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Establishment Labs Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41171200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $420.36 Million | 791.72% |
| Other Comprehensive Income | $3.29 Million | 6.19% |
| Other Components | $74.14 Million | 139.63% |
| Total Equity | $53.09 Million | 100.00% |
Establishment Labs Holdings Inc Competitors by Market Cap
The table below lists competitors of Establishment Labs Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GuoChuang Software Co Ltd
SHE:300520
|
$1.10 Billion |
|
Seojin System Co.Ltd
KQ:178320
|
$1.10 Billion |
|
Energix - Renewable Energies Ltd.
PINK:ENREF
|
$1.10 Billion |
|
ATAI Life Sciences BV
NASDAQ:ATAI
|
$1.10 Billion |
|
Soulbrain Co. Ltd
KQ:357780
|
$1.10 Billion |
|
Test Research Inc
TW:3030
|
$1.10 Billion |
|
SpareBank 1 Østlandet
OL:SPOL
|
$1.10 Billion |
|
Zhejiang Jingu Co Ltd
SHE:002488
|
$1.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Establishment Labs Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,395,000 to 53,095,000, a change of 34,700,000 (188.6%).
- Net loss of 84,596,000 reduced equity.
- New share issuances of 99,484,000 increased equity.
- Other comprehensive income increased equity by 1,322,000.
- Other factors increased equity by 18,490,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-84.60 Million | -159.33% |
| Share Issuances | $99.48 Million | +187.37% |
| Other Comprehensive Income | $1.32 Million | +2.49% |
| Other Changes | $18.49 Million | +34.82% |
| Total Change | $- | 188.64% |
Book Value vs Market Value Analysis
This analysis compares Establishment Labs Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 34.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.43 | $65.01 | x |
| 2017-12-31 | $-0.27 | $65.01 | x |
| 2018-12-31 | $4.00 | $65.01 | x |
| 2019-12-31 | $1.93 | $65.01 | x |
| 2020-12-31 | $3.21 | $65.01 | x |
| 2021-12-31 | $2.12 | $65.01 | x |
| 2022-12-31 | $-0.33 | $65.01 | x |
| 2023-12-31 | $0.72 | $65.01 | x |
| 2024-12-31 | $1.89 | $65.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Establishment Labs Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -159.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -50.95%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 6.53x
- Recent ROE (-159.33%) is below the historical average (-93.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -111.91% | 0.67x | 0.00x | $-19.52 Million |
| 2017 | 0.00% | -100.62% | 0.61x | 0.00x | $-34.40 Million |
| 2018 | -30.36% | -34.47% | 0.53x | 1.68x | $-28.05 Million |
| 2019 | -96.30% | -42.59% | 0.77x | 2.94x | $-42.11 Million |
| 2020 | -50.85% | -45.02% | 0.54x | 2.09x | $-45.62 Million |
| 2021 | -81.08% | -32.47% | 0.91x | 2.75x | $-46.21 Million |
| 2022 | 0.00% | -46.51% | 0.77x | 0.00x | $-74.39 Million |
| 2023 | -426.76% | -47.53% | 0.61x | 14.60x | $-80.34 Million |
| 2024 | -159.33% | -50.95% | 0.48x | 6.53x | $-89.91 Million |
Industry Comparison
This section compares Establishment Labs Holdings Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Establishment Labs Holdings Inc (ESTA) | $16.36 Million | 0.00% | 19.71x | $1.10 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |